Weight Loss With Exenatide Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Obesity
Interventions
DRUG

Exenatide

Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.

DRUG

Placebo

Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.

BEHAVIORAL

Dietary counseling

All subjects will also receive individualized dietary counseling. Subjects in the placebo group will be counseled to follow a hypocaloric diet.

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Jody Dushay

OTHER